| 199 | 30 | 8 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:探讨多西他赛,奥沙利铂与替吉奧新辅助化疗对晚期胃癌患者肿瘤标志物、血管新生及细胞侵袭分子水平的影响。方法:84例晚期胃癌患者依据随机数据表法平均分为对照组(n=42)和观察组(n=42),对照组患者给予多西他赛,奥沙利铂与氟尿嘧啶方案化疗,观察组患者给予多西他赛,奥沙利铂与替吉奧新辅助化疗,比较治疗前后(化疗3个周期后)患者的肿瘤标志物、血管新生及细胞侵袭分子水平。结果:治疗前组间CEA、CA19-9、VEGF、IGF-1、MMP-2和MMP-9水平差异无统计学意义(P>0.05);治疗后两组CEA、CA19-9、VEGF、IGF-1、MMP-2和MMP-9水平均显著低于治疗前,且观察组水平显著低于对照组,差异有统计学意义(P<0.05)。结论:多西他赛,奥沙利铂与替吉奧新辅助化疗治疗晚期胃癌可有效降低患者血清肿瘤标志物水平,抑制血管新生因子及细胞侵袭分子水平释放,具有重要的临床价值。
Abstract：Objective:To investigate the effect of neoadjuvant chemotherapy of docetaxel,oxaliplatin and S-1 for advanced gastric cancer patients with tumor markers,vascular invasion and cell molecular level in newborn.Methods:A total of84 patients with advanced gastric cancer were randomly divided into control group(n=42)and observation group(n=42)according to the random data table method,patients in the control group were treated with docetaxel,oxaliplatin and fluorouracil chemotherapy,and patients in the observation group were given neoadjuvant chemotherapy with docetaxel,oxaliplatin and S-1,the levels of tumor markers,angiogenesis and cell invasion molecules of the two groups before and after treatment(3 cycles after chemotherapy)were compared Results:there was no significant difference in the levels of CEA,CA19-9,VEGF,IGF-1,MMP-2 and MMP-9 between the two groups before treatment(P>0.05);After treatment,two groups of CEA,CA19-9,VEGF,IGF-1,MMP-2 and MMP-9 were significantly lower than those in the same group before treatment,and the observation group were significantly lower than the control group(P<0.05).Conclusions:Neoadjuvant chemotherapy of docetaxel,oxaliplatin and S-1 for advanced gastric cancer can effectively reduce serum tumor marker levels,inhibition of vascular invasion and cell growth factor release level,has important clinical value.
1 Duffy MJ,Lamerz R,Haglund C,et al.Tumor markers in colorectal cancer,gastric cancer and gastrointestinal stromal cancers:European group on tumor markers 2014guidelines update[J].International journal of cancer,2014,134(11):2513-2522.
2 郭军,刘登湘,王娜,等.健脾滋肾为本的中医辨证论治联合XELOX方案化疗对老年晚期胃癌疗效及生存期的影响观察[J].北京中医药,2015,34(4):317-320.
3 王永宏.胃癌术前CT强化率、灌注参数与血清肿瘤标志物含量、肿瘤病灶增殖分子表达的关系[J].海南医学院学报,2017,23(6):823-826.
4 Kim HS,Ryu MH,Zang DY,et al.Phase II study of docetaxel,oxaliplatin,and S-1therapy in patients with metastatic gastric cancer[J].Gastric Cancer,2016,19(2):579-585.
5 Park I,Ryu MH,Choi YH,et al.A phase II study of neoadjuvant docetaxel,oxaliplatin,and S-1(DOS)chemotherapy followed by surgery and adjuvant S-1chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma[J].Cancer chemotherapy and pharmacology,2013,72(4):815-823.
6 中华人民共和国卫生部医政司.胃癌诊疗规范(2011年版)[J].中国医学前沿杂志:电子版,2012,4(5):62-71.
7 左婷婷,郑荣寿,曾红梅,等.中国胃癌流行病学现状[J].中国肿瘤临床,2017,44(1):52-58.
8 Chen W,Zheng R,Baade P D,et al.Cancer statistics in China,2015[J].CA:a cancer journal for clinicians,2016,66(2):115-132.
9 刘阳,刘婕,刘文.胃癌根治切除术联合5-氟尿嘧啶治疗老年胃癌病人的临床疗效及对免疫功能的影响[J].实用老年医学,2017,31(1):42-45.
10 Téoule P,Trojan J,Bechstein W,et al.Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity after Gastrectomy for Gastric Cancer[J].Digestive surgery,2015,32(4):229-237.
11 Yoshikawa T,Tanabe K,Nishikawa K,et al.Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer:early results of the randomized phase II COMPASS trial[J].Annals of surgical oncology,2014,21(1):213-219.
12 Palmela C,Velho S,Agostinho L,et al.Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer[J].Journal of gastric cancer,2017,17(1):74-87.
13 Nishina T,Boku N,Gotoh M,et al.Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens(JCOG0407)[J].Gastric Cancer,2016,19(3):902-910.
14 Zhao W,Dong S,Duan B,et al.HOTAIR is a predictive and prognostic biomarker for patients with advanced gastric adenocarcinoma receiving fluorouracil and platinum combination chemotherapy[J].American journal of translational research,2015,7(7):1295-1302.
15 Ito S,Sano T,Mizusawa J,et al.A phase II study of preoperative chemotherapy with docetaxel,cisplatin,and S-1followed by gastrectomy with D2plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis:JCOG1002[J].Gastric Cancer,2017,20(2):322-331.
16 Yin LK,Sun XQ,Mou DZ.Value of combined detection of serum CEA,CA72-4,CA19-9and TSGF in the diagnosis of gastric cancer[J].Asian Pac J Cancer Prev,2015,16(9):3867-3870.
17 Liang Y,Wang W,Fang C,et al.Clinical significance and diagnostic value of serum CEA,CA19-9and CA72-4in patients with gastric cancer[J].Oncotarget,2016,7(31):49565-49573.
18 Blank S,Deck C,Dreikhausen L,et al.Angiogenic and growth factors in gastric cancer[J].journal of surgical research,2015,194(2):420-429.
19 吕飒美,张健,吴友伟,等.胃癌组织中幽门螺杆菌感染与增殖、侵袭、血管新生分子的相关性研究[J].海南医学院学报,2016,22(16):1768-1770,1774.
20 Abdel-Rahman O.Targeting vascular endothelial growth factor(VEGF)pathway in gastric cancer:preclinical and clinical aspects[J].Critical reviews in oncology/hematology,2015,93(1):18-27.
21 Park DJ,Thomas NJ,Yoon C,et al.Vascular endothelial growth factor a inhibition in gastric cancer[J].Gastric Cancer,2015,18(1):33-42.
22 Ichikawa W,Terashima M,Ochiai A,et al.Impact of insulinlike growth factor-1receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1for Gastric Cancer[J].Gastric Cancer,2017,20(2):263-273.
23 Lee AYL,Fan CC,Chen YA,et al.Curcumin inhibits invasiveness and epithelial-mesenchymal transition in oral squamous cell carcinoma through reducing matrix metalloproteinase 2,9and modulating p53-E-cadherin pathway[J].Integrative cancer therapies,2015,14(5):484-490.
24 Okada R,Naito M,Hattori Y,et al.Matrix metalloproteinase 9 gene polymorphisms are associated with a multiple family history of gastric cancer[J].Gastric Cancer,2017,20(2):246-253.
基本信息:
DOI：10.13210/j.cnki.jhmu.20171120.029
中图分类号:R735.2
引用信息:
[1]郁昊,代恩荣,王荣锋.多西他赛,奥沙利铂及替吉奥新辅助化疗方案对晚期胃癌患者肿瘤标志物、血管新生及细胞侵袭分子的影响[J].海南医学院学报,2018,24(01):86-89.DOI:10.13210/j.cnki.jhmu.20171120.029.
基金信息:
四川省技术创新资助项目(2016EM03117)~~
2017-11-20
2017-11-20
2017-11-20